# Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

> **NCT06362694** · PHASE2 · RECRUITING · sponsor: **Saint Petersburg State University, Russia** · enrollment: 10 (estimated)

## Conditions studied

- Anaplastic Thyroid Cancer

## Interventions

- **DRUG:** Dabrafenib + Trametinib

## Key facts

- **NCT ID:** NCT06362694
- **Lead sponsor:** Saint Petersburg State University, Russia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-25
- **Primary completion:** 2026-03-25
- **Final completion:** 2026-06-25
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06362694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06362694, "Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06362694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*